5 news items
Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024
AUPH
5 Jun 24
for propensity-matched patients with active LN from ALMS and AURA-LV/AURORA 1 were assessed at three and six months. Patients who received the LUPKYNIS-based
Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation's Spring Clinical Meeting 2024
AUPH
14 May 24
that LUPKYNIS continues to be a cost-effective treatment for lupus nephritis (LN). Cost-effectiveness was assessed with the ICER
Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
AUPH
9 May 24
. Safety and efficacy outcomes for propensity-matched patients with active LN from the AURA-LV plus AURORA 1 studies were assessed at three and six
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
AUPH
2 May 24
complete renal response at every time point assessed through three years, compared to mycophenolate mofetil (MMF) and low-dose glucocorticoids alone
FDA Approves Updated LUPKYNIS (voclosporin) Label To Include Long-Term Data From The AURORA Clinical Program
AUPH
30 Apr 24
. The label now includes three-year data from the AURORA 2 double-blind, placebo-controlled extension study, which assessed the long-term safety
- Prev
- 1
- Next